News | News By Subject | News by Disease News By Date | Search News

Hypoparathyroidism News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Shire (SHPGY)'s $5.2 Billion Bet Pays Off as NPS Pharmaceuticals, Inc. (NPSP)'s Natpara Wins Approval     1/27/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
FDA Staff Review Of NPS Pharmaceuticals, Inc. (NPSP) Drug Natpara Sparks Stock Rebound     9/11/2014
Amgen (AMGN) Thyroid Drug AMG 416 Succeeds In Late Stage Kidney Patient Trial     7/21/2014
NPS Pharmaceuticals, Inc. (NPSP) Hormone-Replacement Drug Works in Phase III Study     11/7/2011
New River Pharmaceuticals Inc. (NRPH) Updates Preclinical Pipeline     8/9/2005
Bone Care International Inc. (BCII) Obtains FDA Approval Of New Indication For Hectorol(R) - A Unique, Pro-Horomone Vitamin D2 Analog Now Approved For Use In Pre-Dialysis Chronic Kidney Disease     4/26/2004

News from Around the Web

Press Releases
Shire (SHPG) Release: CHMP Recommends EU Conditional Marketing Authorisation For Natpar (Parathyroid Hormone) For Patients With Chronic Hypoparathyroidism     2/27/2017
NPS Pharmaceuticals, Inc. (NPSP) Release: FDA Approves Natpara® (Parathyroid Hormone) For Injection As An Adjunct To Calcium And Vitamin D To Control Hypocalcemia In Patients With Hypoparathyroidism     1/26/2015
NPS Pharmaceuticals, Inc. (NPSP) Release: PARADOX Findings Published In Endocrine Practice Describe High Burden Of Illness In Patients With Hypoparathyroidism     7/24/2014
NPS Pharmaceuticals, Inc. (NPSP) Submits Biologic License Application to the FDA for Natpara® in Hypoparathyroidism     10/25/2013
NPS Allelix Inc. (CT:NX) Enrolls First Patient in Global Registry Designed to Characterize the Natural History of Hypoparathyroidism     8/1/2013
NPS Pharmaceuticals, Inc. (NPSP) Release: New Data From REPLACE Study Show Initiation of Bone Remodeling for Natpara®-Treated Patients With Hypoparathyroidism     10/15/2012
NPS Pharmaceuticals, Inc. (NPSP) New Findings from Replace Study Support Potential of Natpara(TM) to Treat Adult Hypoparathyroidism     6/25/2012
NPS Pharmaceuticals, Inc. (NPSP) Reports NatparaTM Phase 3 Results to be Presented at ENDO, the Annual Meeting of The Endocrine Society     6/19/2012
Medication for Hypothyroidism May Boost Fracture Risk, University of Toronto Study     5/4/2011
NPS Pharmaceuticals, Inc. (NPSP) Completes Patient Randomization in Phase 3 Study of NPSP558 in Hypoparathyroidism     3/1/2011
NPS Pharmaceuticals, Inc. (NPSP) Initiates Phase 3 'REPLACE' Study of NPSP558 in Hypoparathyroidism     12/22/2008
Mylan Laboratories Inc. (MYL)'s Levothyroxine Sodium Tablets USP Approved As Generic Equivalent To Levothroid(R)     1/3/2007
Lannett Company, Inc. (LCI) Announces The FDA Has Granted An AB Rating To Synthroid     12/14/2004
American Academy of Ophthalmology Release: Possible Link Found Between Hypothyroidism And Glaucoma In Men     9/1/2004